Biocon Limited, an innovation-led global biopharmaceutical company, announced the inauguration of its first U.S. manufacturing facility in Cranbury, New Jersey, through its wholly owned subsidiary, Biocon Generics Inc. (BGI).
The Honourable Governor of New Jersey, Phil Murphy, served as the guest of honor at the inauguration, which was also attended by Biocon’s Chairperson, Kiran Mazumdar-Shaw, alongside dignitaries, customers, partners, and industry leaders.
Acquired from Eywa Pharma Inc. in 2023, the Oral Solid Dosage (OSD) facility has since seen an investment exceeding USD 30 million to configure a state-of-the-art plant with an annual capacity of 2 billion tablets. Several products have already been commercialized from the site, with many more in the pipeline. This investment strengthens supply chain diversification, manufacturing base expansion, and Biocon’s global footprint.
The Cranbury facility is a strategic milestone for Biocon’s U.S. operations. It will enable faster access to essential therapies, improve supply reliability, and bolster connections with healthcare providers and partners — all of which ultimately benefit patients across the United States.
Kiran Mazumdar-Shaw, Chairperson, Biocon Group, said,
“Biocon’s first U.S. FDA-approved formulations facility in New Jersey marks a new chapter in our journey of global expansion. More than a milestone, it is a reaffirmation of our purpose to serve patients wherever they are. Governor Phil Murphy’s presence at the inauguration highlights the importance of Biocon’s role in fostering innovation, creating job opportunities, and strengthening the U.S. healthcare ecosystem. This facility reflects our long-term commitment to deeper engagement with healthcare providers, innovators, and communities to build a healthier and equitable future.”
Siddharth Mittal, Chief Executive Officer & Managing Director, Biocon Ltd, added,
“We were deeply honored to have Governor Phil Murphy and our Chairperson, Kiran Mazumdar-Shaw, join us in marking this milestone: the Biocon Group’s first U.S. manufacturing facility. This strategic investment brings us closer to patients, healthcare providers, and partners in this important market. Proximity allows us to deliver our vertically integrated, high-quality medicines more efficiently to patients across the United States and in other markets, ensuring supply chain resilience and advancing our mission to expand access to affordable therapies worldwide.”
Governor Murphy remarked,
“We are incredibly grateful that Biocon has chosen the Garden State for its first U.S. manufacturing facility. For years, Biocon has provided high-quality medicines and treatments to millions across the globe. This state-of-the-art facility marks a significant moment in Biocon’s global expansion and reinforces New Jersey’s reputation as the medicine chest to the world.”
